3-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxylic acid methyl ester | 675612-18-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxylic acid methyl ester
• 英文别名: methyl 3-(4-fluorobenzyl)-8-hydroxy-[1,6]naphthyridine-7-carboxylate；methyl 3-[(4-fluorophenyl)methyl]-8-hydroxy-1,6-naphthyridine-7-carboxylate
• CAS: 675612-18-7
• 化学式: C₁₇H₁₃FN₂O₃
• 分子量: 312.3
• InChiKey: KVQMCNIJHPDBTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  72.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxylic acid methyl ester 在 N-碘代丁二酰亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以99%的产率得到3-(4-fluorobenzyl)-8-hydroxy-5-iodo[1,6]naphthyridine-7-carboxylic acid methyl ester
  参考文献：
  名称：

  HETEROCYCLIC COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY

  摘要：

  公开号：

  EP1541558B1
• 作为产物：
  描述：

  5-(4-fluorobenzyl)-3-hydroxymethylpyridine-2-carboxylic acid isopropyl ester 、 对甲苯磺酰甘氨酸甲酯 在 sodium methylate 作用下， 以83%的产率得到3-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxylic acid methyl ester
  参考文献：
  名称：

  EP1714966

  摘要：

  公开号：

文献信息

• Heterocyclic compounds having inhibitory activity against hiv integrase
  申请人：Murai Hitoshi

  公开号：US20060128669A1

  公开（公告）日：2006-06-15

  A heterocyclic compound of the formula (I): wherein B 1 is —C(R 2 )═ or —N═; R 1 ′ is H, etc.; one of R 1 and R 2 is -Z 1 -Z 2 -Z 3 -R 5 wherein Z 1 and Z 3 are independently single bond, optionally substituted alkylene, etc.; Z 2 is single bond, optionally substituted alkylene, etc.; R 5 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R 1 and R 2 is H; -A 1 - is —C(—Y)═C(—R A )—C(—R 3 )═C(—R 4 )—, etc. wherein Y is OH, etc.; R A is —COR 7 wherein R 7 is OH, etc.; one of R 3 and R 4 is carboxy, etc., and the other of R 1 and R 2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.

  化合物的公式（I）为杂环化合物，其中B1为—C（R2）═或—N═; R1'为H等; R1和R2中的一个是—Z1-Z2-Z3-R5，其中Z1和Z3分别为单键，可选地取代的烷基等; Z2为单键，可选地取代的烷基等; R5为可选地取代的芳基，可选地取代的杂环芳基等，而R1和R2中的另一个是H; -A1-为—C（—Y）═C（—RA）—C（—R3）═C（—R4）—等，其中Y为OH等; RA为—COR7，其中R7为OH等; R3和R4中的一个是羧基等，而R1和R2中的另一个是H等，其为前药、药学上可接受的盐以及其溶剂化物，具有抗病毒活性，特别是对HIV整合酶的抑制活性，以及含有该化合物的制药组合物，特别是抗HIV药物。
• Heterocyclic compounds having inhibitory activity against HIV integrase
  申请人：Murai Hitoshi

  公开号：US20060247212A1

  公开（公告）日：2006-11-02

  A heterocyclic compound of the formula (I): wherein B 1 is —C(R 2 )═ or —N═; R 1 ′ is H, etc.; one of R 1 and R 2 is -Z 1 -Z 2 -Z 3 -R 5 wherein Z 1 and Z 3 are independently single bond, optionally substituted alkylene, etc.; Z 2 is single bond, optionally substituted alkylene, etc.; R 1 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R 1 and R 2 is H; -A 1 - is —C(—Y)═C(—R A )—C(—R 3 )═C(—R 4 )—, etc. wherein Y is OH, etc.; R A is —COR 7 wherein R 7 is OH, etc.; one of R 3 and R 4 is carboxy, etc., and the other of R 1 and R 2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.

  化合物的式子为(I)的杂环化合物：其中B1为—C(R2)═或—N═；R1'为H等；R1和R2中的一个为-Z1-Z2-Z3-R5，其中Z1和Z3分别为单键，可选地取代的烷基等；Z2为单键，可选地取代的烷基等；R1为可选地取代的芳基，可选地取代的杂环芳基等，而R1和R2中的另一个为H；-A1-为—C(—Y)═C(—RA)—C(—R3)═C(—R4)—等，其中Y为OH等；RA为—COR7，其中R7为OH等；R3和R4中的一个为羧基等，而R1和R2中的另一个为H等。该化合物的前药、药学上可接受的盐和其溶剂化物具有抗病毒活性，特别是对HIV整合酶的抑制活性，以及含有该化合物的药物组合物，尤其是抗HIV药物。
• Naphthyridine derivatives having inhibitory activity against hiv integrase
  申请人：Taishi Teruhiko

  公开号：US20090227621A1

  公开（公告）日：2009-09-10

  [Problems to be Solved] To provide a novel compound having antiviral activity, especially inhibitory activity against HIV integrase, a pharmaceutical composition, especially anti-HIV drug, containing the same. [Means to Solve the Problem] A compound of the formula: (wherein: R 1 is optionally substituted aralkyl; R 2 and R 3 are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for “optionally substituted” is a noncyclic group); R 4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted carbamoyl” and “optionally substituted amino” may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl) or a salt thereof.

  【需要解决的问题】提供一种具有抗病毒活性，特别是对HIV整合酶具有抑制活性的新型化合物，以及包含该化合物的制药组合物，特别是抗HIV药物。 【解决问题的方法】 化合物的化学式为：（其中：R1是可选取代的芳基甲基；R2和R3分别是氢、可选取代的烷基、可选取代的氨基、可选取代的烯基或可选取代的烷氧基（提供“可选取代”中的每个取代基均为非环状基）；R4是氢、可选取代的羧基、可选取代的甲酰胺基、可选取代的氨基甲酰胺基、可选取代的氨基（在“可选取代的甲酰胺基”、“可选取代的氨基甲酰胺基”和“可选取代的氨基”中，氨基上的取代基可以与相邻的N原子一起形成一个含有可选取代的N原子的杂环环），可选取代的烷基、可选取代的烯基、可选取代的芳基或可选取代的杂环芳基）或其盐。
• Naphthyridine derivatives having inhibitory activity against HIV integrase
  申请人：Shionogi & Co., Ltd.

  公开号：US07919623B2

  公开（公告）日：2011-04-05

  A compound having HIV Integrase Inhibitory activity of the formula: (wherein: R1 is optionally substituted aralkyl; R2 and R3 are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for “optionally substituted” is a noncyclic group); R4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted carbamoyl” and “optionally substituted amino” may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl) or a salt thereof.

  一种具有HIV整合酶抑制活性的化合物的化学式为：（其中：R1是可选择取代的芳基甲基；R2和R3各自独立地为氢、可选择取代的烷基、可选择取代的氨基、可选择取代的烯基或可选择取代的烷氧基（前提是“可选择取代”的每个取代基都是非环状基）；R4为氢、可选择取代的羧基、可选择取代的甲酰胺基、可选择取代的氨基甲酰胺基、可选择取代的氨基（前提是“可选择取代”的“甲酰胺基”、“氨基甲酰胺基”和“氨基”上的取代基可以与相邻的氮原子一起形成含有可选择取代的N原子的杂环环），可选择取代的烷基、可选择取代的烯基、可选择取代的芳基或可选择取代的杂芳基）或其盐。
• HETEROCYCLIC COMPOUND HAVING HIV INTEGRASE INHIBITORY ACTIVITY
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1541558A1

  公开（公告）日：2005-06-15

  A heterocyclic compound of the formula (I): wherein B1 is -C(R2)= or -N=; R1' is H, etc.; one of R1 and R2 is -Z1-Z2-Z3-R5 wherein Z1 and Z3 are independently single bond, optionally substituted alkylene, etc.; Z2 is single bond, optionally substituted alkylene, etc.; R5 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R1 and R2 is H; -A1- is -C(-Y)=C(-RA)-C(-R3)=C(-R4)-, etc. wherein Y is OH, etc.; RA is -COR7 wherein R7 is OH, etc.; one of R3 and R4 is carboxy, etc., and the other of R1 and R2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.

  式 (I) 的杂环化合物： 其中 B1 是 -C(R2)= 或 -N=；R1' 是 H 等；R1 和 R2 中的一个是 -Z1-Z2-Z3-R5，其中 Z1 和 Z3 独立地是单键、任选取代的亚烷基等；Z2 是单键、任选取代的亚烷基等；R5 是任选取代的芳基、任选取代的杂芳基等、R1和R2中的另一个是H；-A1-是-C(-Y)=C(-RA)-C(-R3)=C(-R4)-等，其中Y是OH等；RA是-COR7，其中R7是OH等；R3和R4中的一个是羧基等、R1和R2中的另一个是H等，其原药、其药学上可接受的盐和其溶液，具有抗病毒活性，特别是对HIV整合酶的抑制活性，以及含有其的药物组合物，特别是抗HIV药物。